Table 1.
Population characteristics and univariate analysis on the association between population characteristics and 4 areas of treatment
| Characteristics | Total (N = 1392) | High-risk areaa Limoges (N = 266) | Medium-risk areab Nancy (N = 467) |
Low-risk areac Reims (N = 407) | Very-low-risk aread Amiens (N = 252) |
P-value | ||
|---|---|---|---|---|---|---|---|---|
| Age (years), median (inter-quartile) | 63.0 (56–70) | 64.5 (57–72) | 62.0 (55–68) | 63.0 (56–71) | 63.0 (58–70) | 0.0064 | ||
| Sex | ||||||||
| Male, N (%) | 1091 (78.4) | 199 (74.8) | 368 (78.8) | 329 (80.8) | 195 (77.4) | NS | ||
| Female, N (%) | 301 (21.6) | 67 (25.2) | 99 (21.2) | 78 (19.2) | 57 (22.6) | NS | ||
| Primary cancer locations | ||||||||
| HNSCC, N (%) | 958 (68.8) | 159 (59.8) | 330 (70.7) | 283 (69.5) | 186 (73.8) | 0,003 | ||
| Colorectal, N (%) | 347 (24.9) | 99 (37.2) | 114 (24.4) | 79 (19.4) | 55 (21.8) | < 10− 4 | ||
| CSCC, N (%) | 65 (4.7) | 7 (2.6) | 8 (1.7) | 44 (10.8) | 6 (2.4) | NS | ||
| Cervical, N (%) | 2 (0.1) | 0 | 0 | 1 (0.3) | 1 (0.4) | NS | ||
| Other, N (%) | 20 (1.4) | 1 (0.4) | 15 (3.2) | 0 | 4 (1.6) | NS | ||
| Premedications | ||||||||
| Corticosteroids alone, N (%) | 19 (1.4) | 1 (0.4) | 1 (0.2) | 15 (3.7) | 2 (0.8) | NS | ||
| H1A alone, N (%) | 11 (0.8) | 0 | 4 (0.9) | 7 (1.7) | 0 | NS | ||
| Corticosteroids + H1A, N (%) | 1361 (97.8) | 265 (99.6) | 462 (98.9) | 384 (94.6) | 250 (99.2) | < 10− 4 | ||
| Types of chemotherapy | ||||||||
| Monotherapy, N (%) | 49 (3.5) | 11 (4.1) | 5 (1.1) | 32 (7.9) | 1 (0.4) | NS | ||
| Polychemotherapy, N (%) | 911 (65.5) | 205 (77.1) | 335 (71.7) | 198 (48.6) | 173 (68.6) | NS | ||
| Concomittant radiotherapy, N (%) | 432 (31) | 50 (18.8) | 127 (27.2) | 177 (43.5) | 78 (31) | NS | ||
N, number of patients; HNSCC, head and neck squamous-cell carcinoma; CSCC, cutaneous squamous-cell carcinoma; H1A, histamine-1 receptor antagonist; NS, not significant. a, b, c, d defined according to estimated mean annual regional incidence rates of Lyme disease from Septfons A, et al. Eurosurveillance. 2019;24(11). doi:10.2807/1560-7917.ES.2019.24.11.1800134 [41] : a > 150 / 100,000 inhabitants; b 50–100 / 100,000 inhabitants; c 20–50 / 100,000 inhabitants; d 5–20 / 100,000 inhabitants